Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?

Journal of Hypertension

Volumn 38, Issue 5, 2020, Pages 781-782

  Esler, Murray ^a   Esler, Danielle ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSIN CONVERTING ENZYME 2; ANTIHYPERTENSIVE AGENT; CORONAVIRUS SPIKE GLYCOPROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE; SPIKE GLYCOPROTEIN, COVID-19 VIRUS; VIRUS RECEPTOR;

ADVERSE DRUG REACTION; CORONAVIRUS DISEASE 2019; HEART; HEART FAILURE; HUMAN; HYPERTENSION; INFECTION CONTROL; INFECTION RISK; KIDNEY; NOTE; PANDEMIC; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SALT LOADING; BETACORONAVIRUS; BLOOD; BLOOD PRESSURE; COMPLICATION; CORONAVIRUS INFECTION; PHYSIOLOGY; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; VIROLOGY; VIRUS ENTRY; VIRUS PNEUMONIA;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; BETACORONAVIRUS; BLOOD PRESSURE; CORONAVIRUS INFECTIONS; HUMANS; HYPERTENSION; PANDEMICS; PEPTIDYL-DIPEPTIDASE A; PNEUMONIA, VIRAL; RECEPTORS, VIRUS; SPIKE GLYCOPROTEIN, CORONAVIRUS; VIRUS INTERNALIZATION;

EID: 85082881422     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000002450     Document Type: Note

References (10)

1. Zhou P, Yang X, Wang XG, Hu B, Zhang L, Zhang W,. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; https://doi.org/10.1038/s41586-020-2012-7
2. Zisman LS, Keller RS, Weaver B, Lin Q, Speth R, Bristow M,. Increased angiotensin-(1-7) forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme homologue ACE2. Circulation 2003; 108: 1707-1712.
3. Gallagher PE, Ferrario CM, Tallant EA,. MAP kinase/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptides. Am J Physiol Cell Physiol 2008; 295: C1169-C1174.
4. Jessup JA, Gallagher PE, Averill DB, Brosnihan B, Tallant A, Chappell MC,. Effect of angiotension blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats. Am J Physiol Heart Circ 2006; 291: H2166-H2172.
5. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA,. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 2005; 111: 2605-2610.
6. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM,. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 2004; 43: 970-976.
7. Gottlieb SS, Dickstein K, Fleck E, Kostis J, Levine TB, LeJemtel T,. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993; 88 (4 Pt 1): 1602-1609.
8. Bauer IH, Reams GP, Wu Z, Lau-Sieckman A,. Effects of losartan on the renin-angiotensin-aldosterone axis in essential hypertension. J Hum Hypertens 1995; 9: 237-243.
9. Grossman E, Peleg E, Carroll J, Shamiss A, Rosenthal T,. Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension. Am J Hypertens 1994; 7: 1041-1044.
10. Gavras I, Gavras H,. Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: results from a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group. Curr Med Res Opin 1999; 15: 15-24.